VivoSim Labs Inc. (NASDAQ:VIVS) stock fell more than 26% on Thursday after the biotechnology company announced a private placement priced at 85 cents per share, raising investor concerns about potential shareholder dilution.
Private Placement Sparks Dilution Concerns
VivoSim Labs entered into a securities purchase agreement with a healthcare-focused institutional investor to sell 4.71 million shares (or equivalent securities) and accompanying warrants at a combined effective price of $0.85 per share.
The company raised approximately $4.0 million in gross proceeds before fees and expenses.
The warrants, exercisable at $0.85 per share upon shareholder approval, will remain valid for five years.
The company also plans to amend certain May 2024 warrants covering 520,833 shares by lowering the exercise price from $9.60 to $0.85 per share, subject to shareholder approval, while extending their term to five years from the approval date.
The offering is expected to close around July 17, 2026, with proceeds earmarked for working capital and general corporate purposes.
What VivoSim Labs (VIVS) Does
VivoSim Labs, formerly Organovo Holdings, is a biotechnology company focused on developing FXR314 for inflammatory bowel disease (IBD), including ulcerative colitis (UC).
The company utilizes three-dimensional (3D) human tissues to provide insights into liver and intestinal toxicology, which is increasingly relevant as regulatory bodies move towards refining animal testing requirements.
The recent announcement of a private placement is significant as it reflects the company’s need for capital to support its ongoing research and development efforts.
As VivoSim continues to position itself within the evolving biotech landscape, its ability to secure funding while managing investor sentiment will be crucial for its future growth.
VivoSim Labs Stock Price Action
VIVS Price Action: VivoSim Labs shares were down 26.52% at $0.62 at the time of publication on Thursday, according to Benzinga Pro data.
Photo via Shutterstock
Login to comment